File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

TitleDifferent MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Authors
KeywordsTranslocation
t(14;20)
myeloma
survival
MAFt(14;16)
Issue Date2020
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia and Lymphoma, 2020, v. 61 n. 8, p. 1885-1893 How to Cite?
AbstractThe MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients – 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).
Persistent Identifierhttp://hdl.handle.net/10722/307679
ISSN
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.790
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGoldman-Mazur, S-
dc.contributor.authorJurczyszyn, A-
dc.contributor.authorCastillo, JJ-
dc.contributor.authorWaszczuk-Gajda, A-
dc.contributor.authorGrząśko, N-
dc.contributor.authorRadocha, J-
dc.contributor.authorBittrich, M-
dc.contributor.authorKortüm, KM-
dc.contributor.authorGozzetti, A-
dc.contributor.authorUsnarska-Zubkiewicz, L-
dc.contributor.authorValls, JD-
dc.contributor.authorJayabalan, DS-
dc.contributor.authorNiesvizky, R-
dc.contributor.authorKelman, J-
dc.contributor.authorCoriu, D-
dc.contributor.authorRosiñol, L-
dc.contributor.authorSzukalski, L-
dc.contributor.authorGonzález-Calle, V-
dc.contributor.authorMateos, MV-
dc.contributor.authorJamroziak, K-
dc.contributor.authorHus, I-
dc.contributor.authorAvivi, I-
dc.contributor.authorCohen, Y-
dc.contributor.authorMazur, P-
dc.contributor.authorSuska, A-
dc.contributor.authorChappell, A-
dc.contributor.authorMadduri, D-
dc.contributor.authorChhabra, S-
dc.contributor.authorKleman, A-
dc.contributor.authorHari, P-
dc.contributor.authorDelforge, M-
dc.contributor.authorRobak, P-
dc.contributor.authorGentile, M-
dc.contributor.authorKozłowska, I-
dc.contributor.authorGoldberg, SL-
dc.contributor.authorCzepiel, J-
dc.contributor.authorDługosz-Danecka, M-
dc.contributor.authorSilbermann, R-
dc.contributor.authorOlszewski, AJ-
dc.contributor.authorBarth, P-
dc.contributor.authorMikala, G-
dc.contributor.authorChim, CS-
dc.contributor.authorVesole, DH-
dc.date.accessioned2021-11-12T13:36:13Z-
dc.date.available2021-11-12T13:36:13Z-
dc.date.issued2020-
dc.identifier.citationLeukemia and Lymphoma, 2020, v. 61 n. 8, p. 1885-1893-
dc.identifier.issn1042-8194-
dc.identifier.urihttp://hdl.handle.net/10722/307679-
dc.description.abstractThe MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients – 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal-
dc.relation.ispartofLeukemia and Lymphoma-
dc.rightsAccepted Manuscript (AM) i.e. Postprint This is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectTranslocation-
dc.subjectt(14;20)-
dc.subjectmyeloma-
dc.subjectsurvival-
dc.subjectMAFt(14;16)-
dc.titleDifferent MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients-
dc.typeArticle-
dc.identifier.emailChim, CS: jcschim@HKUCC-COM.hku.hk-
dc.identifier.authorityChim, CS=rp00408-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/10428194.2020.1749605-
dc.identifier.pmid32306794-
dc.identifier.scopuseid_2-s2.0-85083656922-
dc.identifier.hkuros329785-
dc.identifier.volume61-
dc.identifier.issue8-
dc.identifier.spage1885-
dc.identifier.epage1893-
dc.identifier.isiWOS:000527176800001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats